Knight Therapeutics Inc. Stock Börse Stuttgart

Equities

04K

CA4990531069

Pharmaceuticals

Market Closed - Börse Stuttgart 02:14:34 2024-07-12 pm EDT 5-day change 1st Jan Change
3.76 EUR -2.59% Intraday chart for Knight Therapeutics Inc. +1.58% 0.00%

Financials

Sales 2024 * 346M 254M 233M Sales 2025 * 356M 261M 240M Capitalization 584M 428M 393M
Net income 2024 * 2M 1.47M 1.35M Net income 2025 * 13M 9.53M 8.75M EV / Sales 2024 * 1.69 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1.64 x
P/E ratio 2024 *
200 x
P/E ratio 2025 *
56.1 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.54%
More Fundamentals * Assessed data
Dynamic Chart
Knight Therapeutics Announced Normal Course Issuer Bid MT
Knight Therapeutics Brief: Announcing Normal Course Issuer Bid MT
Knight Therapeutics Inc. announces an Equity Buyback for 5,312,846 shares, representing 5.24% of its issued share capital. CI
Knight Therapeutics Inc. authorizes a Buyback Plan. CI
Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1 MT
Transcript : Knight Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024
Knight Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Knight Therapeutics Brief: Q1 Net loss was $4.546 Million; Revenues were $86.604 Million MT
Knight Therapeutics Brief: Entering into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM In Canada and Latin America MT
Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024 CI
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for Jornay Pm® for Canada and Latin America CI
Knight Therapeutics Price Target Raised to $7 at RBC MT
Knight Therapeutics Reports Fourth Quarter Results MT
Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024 CI
Transcript : Knight Therapeutics Inc., Q4 2023 Earnings Call, Mar 21, 2024
More news
1 week-1.57%
Current month-0.53%
1 month-4.57%
3 months-3.59%
More quotes
1 week
3.72
Extreme 3.72
3.86
1 month
3.64
Extreme 3.64
3.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 13-10-31
Founder 56 13-10-31
Director of Finance/CFO - 16-06-19
Members of the board TitleAgeSince
Director/Board Member 74 14-01-05
Founder 56 13-10-31
Director/Board Member 61 12-12-31
More insiders
Date Price Change
24-07-12 3.76 -2.59%
24-07-11 3.86 +1.58%
24-07-10 3.8 +1.60%
24-07-09 3.74 -2.60%
24-07-08 3.84 +0.52%

Delayed Quote Börse Stuttgart, July 12, 2024 at 02:14 pm EDT

More quotes
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.72 CAD
Average target price
7.243 CAD
Spread / Average Target
+26.62%
Consensus